fluoxetine has been researched along with Infarction, Middle Cerebral Artery in 9 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Infarction, Middle Cerebral Artery: NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluoxetine is used to improve cognition, exercise ability, depression, and neurological functions in patients with cerebral ischemic stroke." | 8.02 | The functions of fluoxetine and identification of fluoxetine-mediated circular RNAs and messenger RNAs in cerebral ischemic stroke. ( Cai, Z; Deng, J; Gu, M; Guo, Y; He, Y; Zhang, H; Zhao, C, 2021) |
| "Fluoxetine treatment reduced the infarct size of rats after cerebral ischemia reperfusion injury." | 5.51 | Fluoxetine mitigating late-stage cognition and neurobehavior impairment induced by cerebral ischemia reperfusion injury through inhibiting ERS-mediated neurons apoptosis in the hippocampus. ( Ge, MY; Li, Y; Peng, L; Wang, S; Xu, F; Yin, J; Zhang, G; Zhang, Q, 2019) |
| "Fluoxetine is used to improve cognition, exercise ability, depression, and neurological functions in patients with cerebral ischemic stroke." | 4.02 | The functions of fluoxetine and identification of fluoxetine-mediated circular RNAs and messenger RNAs in cerebral ischemic stroke. ( Cai, Z; Deng, J; Gu, M; Guo, Y; He, Y; Zhang, H; Zhao, C, 2021) |
| " Finally, we used therapeutic interventions to explore mechanisms that may be involved in producing this increase in jump latency by administering the anti-depressant fluoxetine prior to the long jump assay, and also tested for potential changes in anxiety levels after stroke." | 3.81 | So you think you can jump? A novel long jump assessment to detect deficits in stroked mice. ( Hurn, PD; Kumar, S; Martin, L; Mittal, N; Ofomata, A; Palmateer, J; Pan, J; Pandya, A; Schallert, T, 2015) |
| "Fluoxetine treatment reduced the infarct size of rats after cerebral ischemia reperfusion injury." | 1.51 | Fluoxetine mitigating late-stage cognition and neurobehavior impairment induced by cerebral ischemia reperfusion injury through inhibiting ERS-mediated neurons apoptosis in the hippocampus. ( Ge, MY; Li, Y; Peng, L; Wang, S; Xu, F; Yin, J; Zhang, G; Zhang, Q, 2019) |
| "The fluoxetine-treated brain was found to show marked repressions of microglia activation, neutrophil infiltration, and proinflammatory marker expressions." | 1.35 | Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. ( Kim, C; Kim, SW; Lee, JK; Lim, CM; Park, JY; Yoon, SH, 2009) |
| "Animals were treated with permanent middle cerebral artery occlusion followed by an 18 day CUMS procedure." | 1.35 | Notch1 signaling, hippocampal neurogenesis and behavioral responses to chronic unpredicted mild stress in adult ischemic rats. ( Guo, YJ; Sui, YX; Sun, Y; Wang, SH; Zhang, ZJ, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Q | 1 |
| Liu, L | 1 |
| Zhou, L | 1 |
| Lu, H | 1 |
| Wang, J | 1 |
| Chen, X | 1 |
| Wang, Q | 1 |
| Li, A | 1 |
| Tian, J | 1 |
| Yang, J | 1 |
| Ren, X | 1 |
| Zhou, Z | 1 |
| Zhou, W | 1 |
| He, Y | 1 |
| Zhang, H | 1 |
| Deng, J | 1 |
| Cai, Z | 1 |
| Gu, M | 1 |
| Zhao, C | 1 |
| Guo, Y | 1 |
| Xu, F | 1 |
| Zhang, G | 1 |
| Yin, J | 1 |
| Zhang, Q | 1 |
| Ge, MY | 1 |
| Peng, L | 1 |
| Wang, S | 1 |
| Li, Y | 1 |
| Hua, Y | 1 |
| Li, C | 1 |
| Hu, J | 1 |
| Wang, YY | 1 |
| Liu, PL | 1 |
| Gao, BY | 1 |
| Chen, C | 1 |
| Xu, DS | 1 |
| Zhang, B | 1 |
| Bai, YL | 1 |
| Mittal, N | 1 |
| Pan, J | 1 |
| Palmateer, J | 1 |
| Martin, L | 1 |
| Pandya, A | 1 |
| Kumar, S | 1 |
| Ofomata, A | 1 |
| Hurn, PD | 1 |
| Schallert, T | 1 |
| Li, WL | 1 |
| Cai, HH | 1 |
| Wang, B | 1 |
| Chen, L | 1 |
| Zhou, QG | 1 |
| Luo, CX | 1 |
| Liu, N | 1 |
| Ding, XS | 1 |
| Zhu, DY | 1 |
| Lim, CM | 1 |
| Kim, SW | 1 |
| Park, JY | 1 |
| Kim, C | 1 |
| Yoon, SH | 1 |
| Lee, JK | 1 |
| Guo, YJ | 1 |
| Zhang, ZJ | 1 |
| Wang, SH | 1 |
| Sui, YX | 1 |
| Sun, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction[NCT02386475] | Phase 4 | 39 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 other studies available for fluoxetine and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Effect of fluoxetine on HIF-1α- Netrin/VEGF cascade, angiogenesis and neuroprotection in a rat model of transient middle cerebral artery occlusion.
Topics: Animals; Disease Models, Animal; Fluoxetine; Hypoxia-Inducible Factor 1, alpha Subunit; Infarction, | 2020 |
Expression of fibroblast growth factor 9 and its receptors in the dentate gyrus of hippocampus in poststroke depression rats.
Topics: Animals; Dentate Gyrus; Depression; Depressive Disorder; Disease Models, Animal; Down-Regulation; Fi | 2021 |
The functions of fluoxetine and identification of fluoxetine-mediated circular RNAs and messenger RNAs in cerebral ischemic stroke.
Topics: Animals; Cerebral Cortex; Fluoxetine; High-Throughput Nucleotide Sequencing; Infarction, Middle Cere | 2021 |
Fluoxetine mitigating late-stage cognition and neurobehavior impairment induced by cerebral ischemia reperfusion injury through inhibiting ERS-mediated neurons apoptosis in the hippocampus.
Topics: Animals; Apoptosis; Brain Ischemia; Cognition; Endoplasmic Reticulum Stress; Fluoxetine; Hippocampus | 2019 |
Fluoxetine adjunct to therapeutic exercise promotes motor recovery in rats with cerebral ischemia: Roles of nucleus accumbens.
Topics: Animals; Brain Ischemia; Exercise Therapy; Fluoxetine; Infarction, Middle Cerebral Artery; Male; Mot | 2019 |
So you think you can jump? A novel long jump assessment to detect deficits in stroked mice.
Topics: Animals; Anxiety; Disease Models, Animal; Female; Fluoxetine; Hindlimb; Infarction, Middle Cerebral | 2015 |
Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke.
Topics: Analysis of Variance; Animals; Antimetabolites; Bromodeoxyuridine; Cell Count; Cognition Disorders; | 2009 |
Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cells, Cultured; Cognition Disorders; | 2009 |
Notch1 signaling, hippocampal neurogenesis and behavioral responses to chronic unpredicted mild stress in adult ischemic rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Bromodeoxyuridine; Conditioning, Operant; Disease M | 2009 |